Jimmy Butts is the Chief Investment Strategist for Maximum Profit and Capital Wealth Letter, and a regular contributor to StreetAuthority Insider. Prior to joining StreetAuthority, Jimmy came from the financial services and banking industry where he worked as a Financial Advisor. There he specialized in providing customized retirement solutions for individuals. Jimmy graduated from Boise State University with a degree in business administration and finance. He also spent multiple years studying language, international business and finance in both Germany and Buenos Aires, Argentina. At one point he held his series 6, 63, 65 and 26 securities licenses. When he's not combing through financial statements or reading about finance, Jimmy enjoys being outdoors.
Analyst Articles
The actions of these bold visionaries led to one of the largest eras of wealth creation in human history -- one that's still happening today. Learn more... Read More
The actions of these bold visionaries led to one of the largest eras of wealth creation in human history -- one that's still happening today. Learn more... Read More
Make no mistake, we are not out of the Covid woods just yet. But the news from Pfizer may be clearing a trail for further gains ahead... Read More
Make no mistake, we are not out of the Covid woods just yet. But the news from Pfizer may be clearing a trail for further gains ahead... Read More
In the short term, it should pay off to be aggressive. But in the long run, I will remain cautious... Read More
In the short term, it should pay off to be aggressive. But in the long run, I will remain cautious... Read More
A split government reduces risk in some sectors, especially in the energy sector. Here's how I'm trading this likely scenario... Read More
A split government reduces risk in some sectors, especially in the energy sector. Here's how I'm trading this likely scenario... Read More
Shares of SPS Commerce (Nasdaq: SPSC) have topped our first profit target price of $93.46 a share — a 25% increase over our entry price. That means it’s time to take some profits (one-third to be exact) off the table. Many stocks are soaring higher on positive Covid-19 vaccine… Read More
If you're looking for income, downside protection, and some upside to boot), it's hard to beat farmland. Here's an easy way to invest... Read More
If you're looking for income, downside protection, and some upside to boot), it's hard to beat farmland. Here's an easy way to invest... Read More
One outcome appears certain -- there is unlikely to be a mandate for Democrats. This seems to be leading to a rally in stocks and bonds. Read More
One outcome appears certain -- there is unlikely to be a mandate for Democrats. This seems to be leading to a rally in stocks and bonds. Read More
One of the most disciplined energy producers just pulled the trigger on a major deal that will create the nation's largest independent producer. Here's why it may be time to buy... Read More
One of the most disciplined energy producers just pulled the trigger on a major deal that will create the nation's largest independent producer. Here's why it may be time to buy... Read More
M&A activity was quiet during the Covid lockdowns, but now it's picking back up at a faster pace than before. Here's what you need to know... Read More
M&A activity was quiet during the Covid lockdowns, but now it's picking back up at a faster pace than before. Here's what you need to know... Read More
Shares of drug manufacturer, Catalent (NYSE: CTLT) have surged following its better-than-expected earnings release November 3. The company topped estimates for both sales and earnings. Catalent posted sales of $845.7 million, beating the consensus by $34.3 million, while earnings came in at $0.43 per share, a 17% surprise. The… Read More
